Kiora Pharmaceuticals, Inc.
KPRX
$2.84
$0.1917.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -- | -- | -- |
| Total Other Revenue | -100.00% | -- | -- | -- | -- |
| Total Revenue | -100.00% | -99.88% | -- | -- | -- |
| Cost of Revenue | 69.87% | -63.45% | -159.24% | -84.31% | -91.07% |
| Gross Profit | -103.88% | -104.08% | 4,071.33% | 510.71% | 491.15% |
| SG&A Expenses | 8.19% | 22.29% | 18.85% | -8.36% | -16.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.16% | -0.70% | 20.13% | 6.52% | -4.46% |
| Operating Income | -251.27% | -255.51% | 164.22% | 165.41% | 161.80% |
| Income Before Tax | -401.07% | -440.33% | 145.56% | 143.87% | 126.94% |
| Income Tax Expenses | 2,198.89% | 2,323.03% | 2,186.82% | 179.91% | 179.91% |
| Earnings from Continuing Operations | -474.44% | -529.20% | 128.73% | 143.55% | 126.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -474.44% | -529.20% | 128.73% | 143.55% | 126.45% |
| EBIT | -251.27% | -255.51% | 164.22% | 165.41% | 161.80% |
| EBITDA | -250.35% | -254.12% | 164.83% | 166.02% | 162.42% |
| EPS Basic | 56.16% | 78.25% | 108.65% | 101.53% | 92.41% |
| Normalized Basic EPS | -64.72% | 73.32% | 115.34% | 103.35% | 98.50% |
| EPS Diluted | 62.99% | 80.08% | 104.15% | 98.50% | 91.01% |
| Normalized Diluted EPS | 16.97% | 77.03% | 109.34% | 99.81% | 97.02% |
| Average Basic Shares Outstanding | 91.74% | 245.18% | 604.44% | 696.12% | 952.02% |
| Average Diluted Shares Outstanding | 71.75% | 185.93% | 650.38% | 762.55% | 1,074.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |